All cancer patients in drug trial appear to be cured for the first time

A new drug being tested for colorectal cancer has left doctors shocked after it returned a 100 per cent success rate in clinical trials.

The drug Dostarlimab is a laboratory-produced molecule that acts as substitute antibodies in the human body, leaving scientists stunned after all 18 participants were considered in remission one-year following the drug trial.

Doctors conducted extensive physical exams and were unable to find any trace of cancer in their bodies.

Dr. Luis A. Diaz Jr. of New York’s Memorial Sloan Kettering Cancer Center said this was ‘the first time this has happened in the history of cancer.’

Dr. Diaz and a team of researchers published a paper on their findings in the New England Journal of Medicine, describing their phenomenal results.

The findings are now making waves in the medical world, with Dr Alan P. Venook telling the New York Times that complete remission in every single patient is ‘unheard of’.

The 18 rectal cancer patients involved faced gruelling previous treatments, such as chemotherapy, radiation and invasive surgery that could result in bowel, urinary dysfunction.

The patients went into the trial expecting to have to go through these as the next step, but instead, no further treatment was needed.

Memorial Sloan Kettering Cancer Center and a co-author of the paper, oncologist Dr. Andrea Cercek, described the moment patients found out they were cancer-free.

“There were a lot of happy tears,” she said.

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 135 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 52 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. cancer cure patients

The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and biomedical research around the world.

Source: Agencies cancer cure patients